The THOR 5th percentile female dummy (THOR-05F) was evaluated for two seating postures/positions in frontal impacts using a generic automotive seat environment. The conditions included 2 crash pulses: a 15 km/h test that utilized 4.5 g acceleration and a 3-point restraint with 2 kN load limiter, and a 32 km/h test that utilized 9.5 g acceleration and a 3-point restraint with a 4.5 kN load limiter and pretensioner, and two seatback angles: 25°, a nominal upright posture, and 45°, a moderate reclined posture. The BRS scores were calculated using the NHTSA BioRank method. Overall biofidelity rating was consider excellent for both seating postures. This evaluation provides an understanding of the THOR-05F response and biofidelity evaluation of the ATD in two seating postures (nominal and reclined). This is essential in the assessment and development of safety measures in emerging ADS-equipped vehicles.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.aap.2023.107185 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Investigation of the mechanical characteristics of porcine brain tissue in complex environments.
Acta Bioeng Biomech
June 2024
1School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China.
: Brain tissue immersed in cerebrospinal fluid often exhibits complex mechanical behaviour, especially the nonlinear stress- strain and rate-dependent responses. Despite extensive research into its material properties, the impact of solution environments on the mechanical behaviour of brain tissue remains limited. This knowledge gap affects the biofidelity of head modelling.
View Article and Find Full Text PDFA phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors.
Oncologist
January 2025
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, United States.
Objectives: Well-differentiated neuroendocrine tumors (NET) are highly vascular tumors characterized by their expression of vascular endothelial growth factor (VEGF). This trial investigated the activity of ramucirumab, a monoclonal antibody that targets VEGF receptor-2 (VEGFR-2) and inhibits activity of VEGF, in combination with somatostatin analog therapy in patients (pts) with advanced extra-pancreatic NET.
Methods: We conducted a single-arm phase II trial enrolling pts with advanced, progressive extra-pancreatic NET.
From MRI to FEM: an automated pipeline for biomechanical simulations of vertebrae and intervertebral discs.
Front Bioeng Biotechnol
January 2025
Institute for Neuroradiology, TUM University Hospital, School of Medicine and Health, Technical University of Munich, Munich, Germany.
Introduction: Biomechanical simulations can enhance our understanding of spinal disorders. Applied to large cohorts, they can reveal complex mechanisms beyond conventional imaging. Therefore, automating the patient-specific modeling process is essential.
View Article and Find Full Text PDFQuasi-Static Mechanical Biomimetics Evaluation of Car Crash Dummy Skin.
Biomimetics (Basel)
December 2024
China Automotive Technology and Research Center, Tianjin 300300, China.
Accurate replication of soft tissue properties is essential for the development of car crash test dummy skin to ensure the precision of biomechanical injury data. However, the intricacy of multi-layer soft tissue poses challenges in standardizing the development and testing of dummy skin materials to emulate soft tissue properties. This study presents a comprehensive testing and analysis of the compressive mechanical properties of both single and multi-layered soft tissues and car crash dummy skin materials, aiming to enhance the biofidelity of dummy skin.
View Article and Find Full Text PDFEvaluation of the ASPYRE-Lung targeted variant panel: a rapid, low-input solution for non-small cell lung cancer biomarker testing and experience from three independent sites.
Transl Lung Cancer Res
November 2024
Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Background: Many patients with non-small cell lung cancer (NSCLC) lack access to highly effective approved targeted therapeutics due to multiple gaps in biomarker testing. Challenges in comprehensive molecular testing include complexities associated with the need to assess the presence of multiple variants, costs of running multiple sequential assays per sample, high assay quality control (QC) failure rates, clinical need for rapid turn-around time (TAT) to initiate therapy, and insufficient tissue samples. The ASPYRE-Lung NSCLC assay addresses gaps in multiplexed testing by simultaneously analyzing DNA and RNA, detecting 114 actionable genomic variants across 11 genes, consistent with current NSCLC treatment guidelines.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!